Scholar Rock Announces Positive Phase 2 Trial Results

Scholar Rock Holding ( (SRRK) ) just unveiled an update.

On June 18, 2025, Scholar Rock announced positive results from its Phase 2 EMBRAZE clinical trial, which evaluated the combination of apitegromab and tirzepatide in preserving lean mass during weight loss in obese patients. The trial demonstrated that apitegromab preserved 54.9% of lean mass compared to tirzepatide alone, indicating a higher quality of weight loss. These results support the potential of apitegromab as a treatment to improve weight loss outcomes by preserving lean muscle mass, which could have significant implications for patients undergoing GLP therapies. The trial’s success reinforces Scholar Rock’s position in the biopharmaceutical industry as a leader in developing innovative treatments for neuromuscular and metabolic disorders.

The most recent analyst rating on (SRRK) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Scholar Rock Holding stock, see the SRRK Stock Forecast page.

Spark’s Take on SRRK Stock

According to Spark, TipRanks’ AI Analyst, SRRK is a Neutral.

Scholar Rock’s overall stock score reflects significant challenges due to financial underperformance, including a lack of revenue and ongoing losses. Despite these issues, positive strides in its SMA program and strategic leadership changes indicate potential for future growth. Mixed technical indicators and a weak valuation further moderate the outlook.

To see Spark’s full report on SRRK stock, click here.

More about Scholar Rock Holding

Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing therapies for patients with spinal muscular atrophy (SMA) and other severe neuromuscular diseases. The company specializes in targeting the transforming growth factor beta (TGFβ) superfamily and aims to advance treatments for neuromuscular diseases, cardiometabolic disorders, and cancer.

Average Trading Volume: 1,264,933

Technical Sentiment Signal: Buy

Current Market Cap: $3.05B

Find detailed analytics on SRRK stock on TipRanks’ Stock Analysis page.